Thursday 16 October, 2025
Objectives: Insulin kinetics is an essential component of glucose homeostasis. Due to system complexity and limited data availability, models of…
Read morePoster: Drug/Disease Modelling - Endocrine
M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus
Thursday 16 October, 2025
Objectives: The objective of this modelling and simulation study was to further characterize the efficacy of empagliflozin (EMPA) 2.5 mg…
Read moreThe population PKPD of unacylated and acylated ghrelin following single rising doses of BI 1356225 in healthy subjects is impacted by the time since last meal
Thursday 16 October, 2025
Introduction/Objectives: BI 1356225 is an inhibitor of the ghrelin O-acyl transferase (GOAT) enzyme. GOAT activates unacylated ghrelin (UAG) via acylation…
Read moreTarget-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy
Thursday 16 October, 2025
Objectives: RG6206 (RO7239361) is a fully human anti-myostatin adnectin-IgG1-Fc-fusion protein that binds to and neutralizes the biological activity of myostatin,…
Read moreFrom glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies.
Thursday 16 October, 2025
Objectives: Finerenone (Kerendia) is used to treat chronic kidney disease in patients with type 2 diabetes. In addition to effects on…
Read moreTransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology
Thursday 16 October, 2025
Introduction: Achondroplasia (ACH) is a rare genetic form of skeletal dysplasia associated with a range of clinical manifestations and complications,…
Read moreSimilar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide
Thursday 16 October, 2025
Objectives: Semaglutide is a glucagon-like peptide-1 analogue formulated both as an approved once-weekly subcutaneous (s.c.) injection and a once-daily oral…
Read moreThe impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin
Thursday 16 October, 2025
Introduction: In critically ill patients, marked changes in pharmacokinetics and pharmacodynamics occur due to, for example, increased distribution volume and…
Read moreMulti-species translational PK/PD modelling in type 2 diabetes
Thursday 16 October, 2025
Objectives: In preclinical research, pharmacokinetic/pharmacodynamic (PK/PD) modelling is very helpful in the drug development. The PK/PD model developped in mice was…
Read moreModel-informed Precision Dosing of Endogenous Hormones: Focusing on Progesterone and Estradiol
Thursday 16 October, 2025
Introduction The world’s demographic is shifting rapidly with individuals aged 65 and older projected to reach 2.2 billion by the…
Read more